Impact of gene expression of NFE2L2 on serum superoxide dismutase and hemeoxygenase‑1 levels in patients with type 2 diabetes and retinopathy

Mhaibes,Sarah Hashim; Ali,Shatha H.

doi:10.3892/wasj.2024.280

Impact of gene expression of NFE2L2 on serum superoxide dismutase and hemeoxygenase‑1 levels in patients with type 2 diabetes and retinopathy

Authors:
- Sarah Hashim Mhaibes
- Shatha H. Ali
View Affiliations

Affiliations: Department of Clinical Laboratory Sciences, College of Pharmacy, University of Baghdad, Baghdad 00961, Iraq
Published online on: September 18, 2024 https://doi.org/10.3892/wasj.2024.280
Article Number: 65
Copyright : © Mhaibes et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic retinopathy (DR) is a serious consequence of diabetes that is caused by reactive oxygen species (ROS) generated under conditions of oxidative stress. The nuclear factor erythroid‑2‑related factor 2 (NFE2L2) plays a critical endogenous protective role against oxidative stress, as it controls the expression of superoxide dismutase (SOD) and heme oxygenase‑1 (HO‑1) genes. The aim of the present study was to determine the gene expression level of NFE2L2 and its association with SOD and HO‑1 serum levels among patients with type 2 diabetes and retinopathy. The present study included 90 patients diagnosed with type 2 diabetes mellitus (48 females and 42 males), aged 40 to 80 years. The patients were divided into two groups as follows: Group A included 60 patients diagnosed with diabetic retinopathy (DR) [among them were 29 patients with non‑proliferative DR (NPDR) and 31 patients with proliferative DR (PDR)] and group B included 30 diabetic patients without any evidence of DR (DWR), considered as the control group to be enrolled in the study. The results revealed significantly lower serum levels of SOD and HO‑1 among the patients with PDR and NPDR, compared with the patients in the DWR group. However, no significant differences were noted between the PDR and NPDR groups as regards the SOD and HO‑1 levels. Of note, the gene expression of NFE2L2 was 3‑fold higher in the DR groups compared with the DWR group. The gene expression of NFE2L2 also exhibited a significant negative correlation with the serum SOD and HO‑1 levels in the DR groups. Furthermore, the decline in SOD and HO‑1 activity in the DR groups indicated the consumption of antioxidant capacity for detoxifying ROS due to uncontrolled hyperglycemia, thus, increasing the expression of NFE2L2 to counteract the oxidative stress in DR. On the whole, the present study demonstrates that NFE2L2 expression may be a good indicator of the progression of DR.

View Figures

View References

1	Faris Raheem M, Ali SH, Al-Nuaimi AMA and Shareef GL: Impact of serum vitamin D level on selected bone-related markers in obese-type 2 diabetes patients. [version 1; peer review: awaiting peer review]. F1000Research. 12(56)2023.
2	Ali IA and Ali SH: Impact of osteocalcin level on vascular calcification in type 2 diabetics in relation to fibroblast growth factor-23 (FGF-23). Iraqi J Pharm Sci. 27:42–54. 2018.
3	Shaheed HS and Ali SH: Association of carnosinase-1 gene polymorphism with serum carnosine and carnosinease-1 isoform levels in type 2 diabetics with cardiovascular diseases in Iraq. Al-Rafidain J Med Sci. 4:109–117. 2023.
4	Kadhim SA, Saleh ES and Jaafer AD: Assessment of serum levels of advanced oxidation protein products in type 2 diabetic patients with and without retinopathy taking different antidiabetic treatments. Iraqi J Pharm Sci. 32:74–82. 2023.
5	Gui F, You Z, Fu S, Wu H and Zhang Y: Endothelial dysfunction in diabetic retinopathy. Front Endocrinol (Lausanne). 11(591)2020.PubMed/NCBI View Article : Google Scholar
6	Mhaibes SH and Ali SH: Biomarkers of oxidative stress in diabetic microvascular complications. Iraqi J Pharm Sci. 33(3)2024.(In press).
7	He F, Ru X and Wen T: NRF2, a transcription factor for stress response and beyond. Int J Mol Sci. 21(4777)2020.PubMed/NCBI View Article : Google Scholar
8	Xu X, Luo P, Wang Y, Cui Y and Miao L: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) is a novel therapeutic target for diabetic complications. J Int Med Res. 41:13–19. 2013.PubMed/NCBI View Article : Google Scholar
9	Zhao Z, Chen Y, Wang J, Sternberg P, Freeman ML, Grossniklaus HE and Cai J: Age-related retinopathy in NRF2-deficient mice. PLoS One. 6(e19456)2011.PubMed/NCBI View Article : Google Scholar
10	Xu Z, Wei Y, Gong J, Cho H, Park JK, Sung ER, Huang H, Wu L, Eberhart C, Handa JT, et al: NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia. 57:204–213. 2014.PubMed/NCBI View Article : Google Scholar
11	Kumar A and Mittal R: Nrf2: A potential therapeutic target for diabetic neuropathy. Inflammopharmacology. 25:393–402. 2017.PubMed/NCBI View Article : Google Scholar
12	Dodson M, Shakya A, Anandhan A, Chen J, Garcia JGN and Zhang DD: NRF2 and diabetes: The good, the bad, and the complex. Diabetes. 71:2463–2476. 2022.PubMed/NCBI View Article : Google Scholar
13	Solomon SD and Goldberg MF: ETDRS grading of diabetic retinopathy: Still the gold standard? Ophthalmic Res. 62:190–195. 2019.PubMed/NCBI View Article : Google Scholar
14	American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of care in diabetes-2024. Diabetes Care. 47 (Suppl 1):S20–S42. 2024.PubMed/NCBI View Article : Google Scholar
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
16	Deliyanti D, Alrashdi SF, Tan SM, Meyer C, Ward KW, de Haan JB and Wilkinson-Berka JL: Nrf2 activation is a potential therapeutic approach to attenuate diabetic retinopathy. Invest Ophthalmol Vis Sci. 59:815–825. 2018.PubMed/NCBI View Article : Google Scholar
17	Li C, Miao X, Li F, Wang S, Liu Q, Wang Y and Sun J: Oxidative stress-related mechanisms and antioxidant therapy in diabetic retinopathy. Oxid Med Cell Longev. 2017(9702820)2017.PubMed/NCBI View Article : Google Scholar
18	Sun Y, Xiu C, Liu W, Tao Y, Wang J and Qu YI: Grape seed proanthocyanidin extract protects the retina against early diabetic injury by activating the Nrf2 pathway. Exp Ther Med. 11:1253–1258. 2016.PubMed/NCBI View Article : Google Scholar
19	Cao Y, Li X, Wang CJ, Li P, Yang B, Wang CB and Wang LX: Role of NF-E2-related factor 2 in neuroprotective effect of l-carnitine against high glucose-induced oxidative stress in the retinal ganglion cells. Biomed Pharmacother. 69:345–348. 2015.PubMed/NCBI View Article : Google Scholar
20	B Domènech E and Marfany G: The relevance of oxidative stress in the pathogenesis and therapy of retinal dystrophies. Antioxidants (Basel). 9(347)2020.PubMed/NCBI View Article : Google Scholar
21	Fan J, Xu G, Jiang T and Qin Y: Pharmacologic induction of heme oxygenase-1 plays a protective role in diabetic retinopathy in rats. Invest Ophthalmol Vis Sci. 53:6541–6556. 2012.PubMed/NCBI View Article : Google Scholar
22	Bucolo C, Drago F, Maisto R, Romano GL, D'Agata V, Maugeri G and Giunta S: Curcumin prevents high glucose damage in retinal pigment epithelial cells through ERK1/2-mediated activation of the Nrf2/HO-1 pathway. J Cell Physiol. 234:17295–17304. 2019.PubMed/NCBI View Article : Google Scholar
23	Kanwar M, Chan PS, Kern TS and Kowluru RA: Oxidative damage in the retinal mitochondria of diabetic mice: Possible protection by superoxide dismutase. Invest Ophthalmol Vis Sci. 48:3805–3811. 2007.PubMed/NCBI View Article : Google Scholar
24	Setareh J, Hoseinzade G, Khoundabi B, Kamali M, Ebrahimi A, Fazlollahpour-Naghibi A, Zareei M, Mohamaditabar M and Makaremi A: Can the level of HbA1C predict diabetic retinopathy among type II diabetic patients? BMC Ophthalmol. 22(415)2022.PubMed/NCBI View Article : Google Scholar
25	Kant D, Kumari J and Singh RK: Correlation of blood sugar and HbA1C levels in different stage of diabetes retinopathy: A hospital based prospective study. Int J Health Sci. 6:1867–1876. 2022.
26	Salih BH, Ali SH and Allehibi KI: Serum aldosterone levels in patients with diabetic nephropathy in relation to vascular calcification. Iraqi J Pharm Sci. 28:53–63. 2019.
27	Hou Y, Lin M, Qiu X, He M, Zhang Y and Guo F: Effect of type-2 diabetes mellitus in retinopathy patients on MDA, SOD activity and its correlation with hba1c. Braz Arch Biol Technol. 64(e21200075)2022.
28	Filla LA and Edwards JL: Metabolomics in diabetic complications. Mol Biosyst. 12:1090–1105. 2016.PubMed/NCBI View Article : Google Scholar
29	Hyttinen JMT, Kannan R, Felszeghy S, Niittykoski M, Salminen A and Kaarniranta K: The Regulation of NFE2L2 (NRF2) signalling and epithelial-to-mesenchymal transition in age-related macular degeneration pathology. Int J Mol Sci. 20(5800)2019.PubMed/NCBI View Article : Google Scholar